(Q46820691)

25 December 2017

title

Impact of biochemical failure on overall survival after radiation therapy for localized prostate cancer in the PSA era. (English)

1 reference

25 December 2017

0 references

1 reference

1

Patrick A Kupelian

1 reference

25 December 2017

author name string

Jeffrey C Buchsbaum

2

1 reference

25 December 2017

Chandrika Patel

3

1 reference

25 December 2017

Mohamed Elshaikh

4

1 reference

25 December 2017

Chandana A Reddy

5

1 reference

25 December 2017

Craig Zippe

6

1 reference

25 December 2017

Eric A Klein

7

1 reference

25 December 2017

language of work or name

English

0 references

publication date

1 March 2002

1 reference

25 December 2017

International Journal of Radiation Oncology Biology Physics

published in

1 reference

25 December 2017

volume

52

1 reference

25 December 2017

page(s)

704-711

1 reference

25 December 2017

issue

3

1 reference

25 December 2017

Higher than standard radiation doses (> or =72 Gy) with or without androgen deprivation in the treatment of localized prostate cancer

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2902778-X

7 January 2021

Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2902778-X

7 January 2021

Significance of normal serum prostate-specific antigen in the follow-up period after definitive radiation therapy for prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2902778-X

7 January 2021

Biochemical failure does not predict overall survival after radical prostatectomy for localized prostate cancer: 10-year results

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2902778-X

7 January 2021

Importance of high radiation doses (72 Gy or greater) in the treatment of stage T1-T3 adenocarcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2902778-X

7 January 2021

Conventional vs. conformal radiotherapy for prostate cancer: preliminary results of dosimetry and acute toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2902778-X

7 January 2021

Defining biochemical cure for prostate carcinoma patients treated with external beam radiation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2902778-X

7 January 2021

Prostate-specific antigen cancer volume: a significant prognostic factor in prostate cancer patients at intermediate risk of failing radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2902778-X

7 January 2021

Prostate-specific antigen. An important marker for prostate cancer treated by external beam radiation therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2902778-X

7 January 2021

Prostate specific antigen as an outcome variable for T1 and T2 prostate cancer treated by radiation therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2902778-X

7 January 2021

Prostate-specific antigen and external beam radiation therapy in prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2902778-X

7 January 2021

Dose selection for prostate cancer patients based on dose comparison and dose response studies

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2902778-X

7 January 2021

Dose escalation with 3D conformal treatment: five year outcomes, treatment optimization, and future directions.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2902778-X

7 January 2021

Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2902778-X

7 January 2021

Declining rates of extracapsular extension after radical prostatectomy: evidence for continued stage migration

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2902778-X

7 January 2021

10.1016/S0360-3016(01)02778-X

Identifiers

DOI

1 reference

25 December 2017

PubMed ID

11849793

1 reference

25 December 2017